Apollo to invest €3bn in life sciences business Bayer
Friday, July 10, 2026 · first reported by PE Hub
Apollo commits €3bn (≈$3.3bn) to acquire Bayer's life sciences business, expanding healthcare portfolio.
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore on Apollo
Everything on this firm →- Antin agrees sale of majority stake in Vicinity Energy to Harrison StreetPrivate Equity Wire +3
- CPP Investments sells A$4.5bn Australian toll road stakes to TransurbanIPE Real Assets
- Sycamore nears $9bn sale of Boots to Weston familyPrivate Equity Wire
- Eagle Point backs $450m US government-leased real estate recapitalisationIPE Real Assets
- CSC acquires 50% Watergardens mall stake from QIC for A$480mIPE Real Assets
- Lone Star buys €216m Dutch residential portfolio from Catella fundIPE Real Assets